Litigation Details for Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc. (N.D.N.Y. 2020)

✉ Email this page to a colleague

Docket	⤷ Subscribe	Date Filed	2020-06-19
Court	District Court, N.D. New York	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	David N. Hurd
Jury Demand	Both	Referred To	Christian F. Hummel
Parties	NOVARTIS PHARMA AG
Patents	9,220,631
Attorneys	Molly Grammel
Firms	Goodwin, Procter Law Firm NY Office
Link to Docket	External link to docket

The biologic drugs covered by the patent cited in this case are ⤷ Subscribe and ⤷ Subscribe .

Subscribe to access the full database, or Subscribe
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2020-06-19	1	Complaint	Regeneron”) for infringement of U.S. Patent No. 9,220,631 (“the ’631 patent”). …unlawfully uses Novartis’s patented syringe technology and infringes the ’631 patent. …the United States Patent and Trademark Office duly and legally issued the ’631 patent, entitled “Syringe…copy of the ’631 patent is attached as Exhibit A. 13. The ’631 patent is valid and presumed…’631 patent necessary to bring this action, including the exclusive right to enforce the patent in the	External link to document
2022-11-07	163		6, 11-13, 17, and 21-25 of U.S. Patent No. 9,220,631 (“the ’631 Patent”); WHEREAS, no trial dates…all claims of the ’631 Patent; WHEREAS, on October 25, 2022, the Patent Trial and Appeal Board…Technology LLC (collectively “Novartis”) brought this patent infringement action accusing Defendant Regeneron…Court. WHEREAS, on October 26, 2021, the Patent Trial and Appeal Board (“PTAB”) instituted an …in IPR2021-00816 finding all claims of the ’631 Patent unpatentable as obvious under 35 U.S.C. § 103;	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document